Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.085
-0.200-2.15%
Volume:92.25M
Turnover:847.04M
Market Cap:104.68B
PE:22.80
High:9.355
Open:9.345
Low:8.910
Close:9.285
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:2.00
T/O Rate:0.80%
Dividend:0.34
Dividend Rate:3.72%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.37
PE(LYR):22.80
PS:2.85

Loading ...

Movement Alert|CSPC PHARMA Falls 3.07% in Regular Trading, Innovative Drug Sector Retreats After Holiday

Market Focus
·
Yesterday

CSPC Pharma Presents Data from Cervical Cancer Study at Gynecologic Cancer Society Meeting

MT Newswires Live
·
Oct 08

CSPC Pharma Unveils Phase I Data for SYS6002 Monotherapy in Advanced Cervical Cancer at IGCS 2026 Rapid Oral Presentation

Stock News
·
Oct 08

CSPC Pharmaceutical Group Stock Sheds 5.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 08

Movement Alert|CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout

Market Focus
·
Oct 08

CSPC Pharmaceutical Group Stock Rises 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 06

CSPC Pharma to Present Updates from Eight Trials at European Oncology Conference

MT Newswires Live
·
Oct 05

CSPC Pharma to Present Eight Oncology Trial Updates, Including Two Late-Breaking Abstracts, at ESMO 2026

Bulletin Express
·
Oct 05

CSPC Pharma to Unveil Eight New Clinical Trial Advances at 2026 ESMO Congress

Stock News
·
Oct 05

CSPC PHARMA Maintains 11.52 Billion Shares Outstanding in September; 1.15 Billion Options Could Add 10% Dilution

Bulletin Express
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Movement Alert|CSPC PHARMA Falls 3.13% in Regular Trading, Trading at HK$9.735

Market Focus
·
Oct 02

CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates

Simply Wall St.
·
Oct 01

CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study

MT Newswires Live
·
Oct 01

CSPC Pharma Announces Positive Phase III Results for Weekly GLP-1 Candidate TG103 in Chinese Type 2 Diabetes Patients

Bulletin Express
·
Sep 30

CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026

Stock News
·
Sep 30

CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 30

AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session

Stock News
·
Sep 30

CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines

Stock News
·
Sep 30

CSPC Hits 5-Week High on US FDA's Nod on Herpes Zoster Vaccine Trial

Reuters
·
Sep 30